Last Price
0.009
Today's Change
-0.005 (35.71%)
Day's Change
0.009 - 0.012
Trading Volume
18,070,419
Profile
CHM
Exchange: Australian Securities Exchange Australian Securities Exchange
Currency: AUD AUD
Sector: Healthcare - Healthcare Healthcare - Healthcare
CEO: Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD Mr. Paul Edward-Alexander Hopper A.S.i.A, B.A (UNSW), FAICD
Full Time Employees: 0 0
IPO Date: 2021-01-17 2021-01-17
ISIN: AU0000121576 AU0000121576
Beta: 1.46 1.46
Last Dividend: 0.00 0.00
Dcf Diff: 0.01 0.01
Dcf: 0.00 0.00
Description
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
Address
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
CEO Morning Brief
Hyundai India Starts US$3.3b IPO in Country's Largest-ever Share Sale
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
